Sera Prognostics (NASDAQ:SERA) CEO Sells 7,022 Shares of Stock

Sera Prognostics, Inc. (NASDAQ:SERA) CEO Zhenya Lindgardt sold 7,022 shares of the firm’s stock in a transaction that occurred on Thursday, September 10th. The stock was sold at an average price of $2.00, for a total transaction of $14,044.00. Following the sale, the chief executive officer directly owned 837,848 shares of the company’s stock, valued at $1,675,696. The trade was a 0.83% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Zhenya Lindgardt also recently made the following trade(s):

• On Tuesday, September 8th, Zhenya Lindgardt sold 20,139 shares of Sera Prognostics stock. The shares were sold at an average price of $2.00, for a total transaction of $40,278.00.

Sera Prognostics Trading Down 2.4%

NASDAQ SERA traded down $0.05 during trading hours on Friday, reaching $2.00. 26,356 shares of the company traded hands, compared to its average volume of 49,381. The stock has a market capitalization of $78.90 million, a PE ratio of -2.99 and a beta of 0.98. Sera Prognostics, Inc. has a 12 month low of $1.56 and a 12 month high of $3.95. The company has a 50 day moving average of $2.05 and a two-hundred day moving average of $2.02.

Sera Prognostics (NASDAQ:SERA) last issued its earnings results on Wednesday, August 12th. The company reported ($0.18) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.15) by ($0.03). Sera Prognostics had a negative net margin of 47,475.72% and a negative return on equity of 46.71%. The company had revenue of $0.03 million during the quarter, compared to analyst estimates of $0.07 million. On average, equities research analysts anticipate that Sera Prognostics, Inc. will post -0.62 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of research analysts have commented on the company. Weiss Ratings downgraded Sera Prognostics from a “sell (d-)” rating to a “sell (e+)” rating in a report on Friday, July 31st. Craig Hallum assumed coverage on Sera Prognostics in a report on Thursday, June 4th. They issued a “buy” rating and a $6.00 price target for the company. One research analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $5.50.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently modified their holdings of the business. AWM Investment Company Inc. bought a new stake in Sera Prognostics in the 2nd quarter valued at about $377,000. Captrust Financial Advisors grew its position in Sera Prognostics by 20.0% in the 2nd quarter. Captrust Financial Advisors now owns 602,277 shares of the company’s stock worth $1,668,000 after purchasing an additional 100,366 shares during the last quarter. Segall Bryant & Hamill LLC acquired a new stake in shares of Sera Prognostics in the first quarter valued at approximately $193,000. Jane Street Group LLC acquired a new stake in shares of Sera Prognostics in the fourth quarter valued at approximately $203,000. Finally, Vanguard Group Inc. raised its holdings in shares of Sera Prognostics by 4.6% during the third quarter. Vanguard Group Inc. now owns 1,217,190 shares of the company’s stock valued at $3,725,000 after buying an additional 54,008 shares during the last quarter. 54.64% of the stock is owned by institutional investors and hedge funds.

Sera Prognostics Company Profile

Sera Prognostics, Inc is a precision medicine company focused on improving pregnancy outcomes through proteomic testing. The company’s flagship product, the PreTRM™ test, is a blood-based assay designed to assess a woman’s risk of delivering prematurely by measuring specific protein biomarkers in maternal serum. By identifying patients at elevated risk for spontaneous preterm birth, Sera Prognostics aims to enable earlier interventions and tailored care plans that can reduce the incidence of neonatal complications associated with early delivery.

Since its founding in 2014 and subsequent initial public offering in 2020, Sera Prognostics has worked closely with clinical research networks and obstetric care providers across the United States to validate the clinical performance of its PreTRM test.